ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2025
0mins
Source: Globenewswire
Clinical Trial Results: Firmonertinib shows a median progression-free survival of 16 months in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC), along with significant central nervous system activity and a favorable safety profile.
Future Developments: ArriVent plans to initiate a pivotal Phase 3 trial (ALPACCA) for firmonertinib in the second half of 2025, aiming for accelerated approval based on promising interim data from ongoing studies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
